There are 702 resources available
33P - Final analysis of the Greek cohort of the AGENT phase III study arfolitixorin in metastatic colorectal cancer
Presenter: Anna Koumarianou
Session: Poster Display session
34P - Circulating tumor DNA (ctDNA) testing in tissue RAS/BRAF wild-type metastatic colorectal carcinoma (mCRC) patients (pts) enrolled in the LIquid BIopsy monoclonal Antibodies (LIBImAb) study
Presenter: Anna Maria Rachiglio
Session: Poster Display session
35P - Neutropenia and efficacy outcomes in patients with refractory mCRC: A post-hoc analysis of the phase III SUNLIGHT trial
Presenter: Gerald Prager
Session: Poster Display session
36P - Exploring the potential of Artificial intelligence: Revolutionizing treatment decision-making in metastatic colorectal cancer
Presenter: Eliza Froicu
Session: Poster Display session
37P - Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in genetically selected microsatellite stable colorectal cancer patients
Presenter: Ian Chau
Session: Poster Display session
38P - Modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for right-sided or BRAF mutant metastatic colorectal cancer (mCRC): Subgroup analysis of the DEEPER trial (JACCRO CC-13)
Presenter: Yu Sunakawa
Session: Poster Display session
40P - Surufatinib combined with PD-1 inhibitors as a late-line therapy in patients with refractory metastatic colorectal cancer (mCRC)
Presenter: Huiting Xu
Session: Poster Display session
41P - Surufatinib plus toripalimab and chemotherapy for second-line treatment of RAS/BRAF mutant (MT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC): A single-arm, phase II study (APHRODITE)
Presenter: Yi Zheng
Session: Poster Display session
42P - Neoadjuvant tislelizumab combined with CAPOX for MSS/pMMR high-risk locally advanced colon cancer: A single-arm, exploratory phase II clinical study
Presenter: Minglin Lin
Session: Poster Display session